Clinical Trial Update: A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus [Phase 3]

View source ↗

Summary

This clinical trial update describes a long-term extension study evaluating the safety of Litifilimab (BIIB059) injections and its potential to improve symptoms…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus
• Subacute Cutaneous Lupus Erythematosus

Drugs mentioned

• Litifilimab (litifilimab)

Snippet

Sponsor: Biogen | Conditions: Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | Phase 3 | Status: ENROLLING_BY_INVITATION